Crinetics Pharmaceuticals (CRNX) Total Liabilities (2017 - 2025)
Crinetics Pharmaceuticals has reported Total Liabilities over the past 9 years, most recently at $134.2 million for Q4 2025.
- For Q4 2025, Total Liabilities rose 22.21% year-over-year to $134.2 million; the TTM value through Dec 2025 reached $134.2 million, up 22.21%, while the annual FY2025 figure was $134.2 million, 22.21% up from the prior year.
- Total Liabilities for Q4 2025 was $134.2 million at Crinetics Pharmaceuticals, up from $123.9 million in the prior quarter.
- Over five years, Total Liabilities peaked at $134.2 million in Q4 2025 and troughed at $14.1 million in Q1 2021.
- A 5-year average of $68.4 million and a median of $66.5 million in 2023 define the central range for Total Liabilities.
- Biggest five-year swings in Total Liabilities: decreased 8.91% in 2021 and later surged 206.48% in 2024.
- Year by year, Total Liabilities stood at $19.1 million in 2021, then surged by 87.97% to $35.8 million in 2022, then surged by 168.49% to $96.2 million in 2023, then rose by 14.07% to $109.8 million in 2024, then grew by 22.21% to $134.2 million in 2025.
- Business Quant data shows Total Liabilities for CRNX at $134.2 million in Q4 2025, $123.9 million in Q3 2025, and $118.0 million in Q2 2025.